AMST

Net loss: US$663.4k (loss narrowed by 54% from 3Q 2024). US$0.16 loss per share (improved from US$0.56 loss in 3Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Amesite shares are up 37% from a week ago. It is worth noting though that we have found 5 warning signs for Amesite that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Company Reports Accelerated Growth for both B2C and B2B, with Outstanding Customer Reviews into Q4 DETROIT, May 16, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced its flagship app NurseMagicTM generated 2.4x revenue from Q2/2025 to Q3/2025, even as the company continued to cut operating expenses. Sarah Berman, Principal Financial and Accounting Officer, said, “Our revenues are presently evenly distributed between B2B and B2C sales. Following the launch of NurseMagicTM in Q4/2024, revenues were stable from Q1/2025 to Q2/2025. However, in Q3/2025, we had a significant increase of 2.4x in revenue, following execution of targeted sales and marketing motions and rollouts of product enhancements. We also further reduced expenses while scaling sales this past quarter, retaining our strong focus on achieving further operational efficiencies and managing margins to drive to profitability.” Brandon Owens, VP of Sales, said, “We delivered Teams Plus+ to our B2B customers in direct response to their need for greater intensity of usage, and expect accelerated business demands for more services, given the feedback. Our product testimonials are our best sales assets, and we are closing sales and onboarding teams within days or weeks, because of the efficiency of our payments and onboarding workflows." Madison Bush, Director of Corporate Operations, said, "We saw user growth of 1340% over Q3, following the launch of paid subscriptions in Q2. We have expanded our mobile marketing and are communicating with our users at every step of their journey to attract and retain them. We are thrilled to see that nurses who are searching for AI-tools are finding and using NurseMagicTM because it delivers incredible value.” Dr. Ann Marie Sastry, CEO and Founder, said, “We are confident that we can continue to deliver NurseMagicTM at an affordable price point to both B2C and B2B customers, while maintaining healthy margins – and look forward to more growth in Q4. Our outstanding customer feedback validates a strong product-market fit. With our nimble development process, we feel that we are in very good position to grow revenue efficiently, while delivering tiered services that enable us to expand into new segments opportunistically.” Amesite is focused on delivering value in large, growing segments, including...